Lifestyle Changes and Medications for Aging Adults

(FOES Trial)

This trial aims to boost movement, thinking, and immune health in aging adults through lifestyle changes, risk management, and medications such as dasatinib, quercetin (a dietary supplement), and vortioxetine (an antidepressant). The trial seeks participants living in Illinois or Missouri, aged 50 to 70, who do not exercise regularly. Participants must be able to visit the research center in St. Louis. This study may suit individuals with a higher body mass index (BMI) or body roundness index who can provide informed consent. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial may require you to stop certain medications if they interact with the study treatments. It's best to discuss your current medications with the trial team to see if any changes are needed.

Research has shown that the combination of dasatinib and quercetin is safe for older adults. Studies indicate it is well-tolerated, even for those who walk slowly or have mild memory problems. No major safety issues have been reported, which is encouraging.

For vortioxetine, one study found it generally safe for older adults as well. Some participants experienced nausea and headaches, but these were the most common side effects. Overall, the treatment seems manageable for most people.

Researchers are excited about this treatment because it combines lifestyle management with medications like dasatinib, quercetin, and vortioxetine, which offer a new approach to managing health risks in aging adults. Unlike standard treatments that might focus solely on one aspect, such as medication or lifestyle changes separately, this intervention is a multicomponent and personalized strategy. Dasatinib and quercetin are particularly interesting because they have potential senolytic properties, meaning they might help clear out damaged cells that contribute to aging. Meanwhile, vortioxetine is known for its antidepressant effects, which could support mental health in older adults. This holistic approach aims to tackle aging-related challenges more comprehensively than current options.

Research has shown that combining dasatinib and quercetin, which participants in this trial may receive, can improve physical and mental abilities. These compounds might reduce inflammation and slow aging. In older adults at risk for Alzheimer's, this combination was well-tolerated and showed potential benefits for the brain. Vortioxetine, an antidepressant included in the treatment arm of this trial, enhanced thinking skills in previous studies. Together, these treatments aim to boost brain function and support healthy aging.⁴⁶⁷⁸⁹